scholarly journals ISMP Adverse Drug Reactions: Allergic Angina Caused by Fluconazole Rhabdomyolysis Caused by Risperidone High Incidence of Hyponatremia With High-Dose Trimethoprim-Sulfamethoxazole Lithium Carbonate-Induced Hypersalivation Persistent Hemorrhage After Idarucizumab Administration

2017 ◽  
Vol 52 (7) ◽  
pp. 455-458 ◽  
Author(s):  
Michael A. Mancano
Keyword(s):  
Adverse Drug Reactions ◽  
Lithium Carbonate ◽  
High Dose ◽  
Drug Reactions ◽  
High Incidence ◽  
Allergic Angina

scholarly journals Safety and tolerability of liquid amikacin in antibiotic-loaded bone cement – a case series

2021 ◽  
Vol 6 (5) ◽  
pp. 147-150
Author(s):  
Don Bambino Geno Tai ◽  
Nathan J. Brinkman ◽  
Omar Abu Saleh ◽  
Douglas R. Osmon ◽  
Matthew P. Abdel ◽  
...  
Keyword(s):  
Bone Cement ◽  
Adverse Drug Reactions ◽  
Case Series ◽  
High Dose ◽  
Drug Reactions ◽  
Joint Infections

Abstract. High-dose liquid antibiotics are uncommon in bone cement. We present a case series of patients in which up to 16 mL of liquid amikacin (250 mg mL−1) was successfully incorporated into bone cement to treat periprosthetic joint infections. We did not observe adverse drug reactions definitively attributed to its use.

scholarly journals ISMP Adverse Drug Reactions: Pheochromocytoma Crisis Induced by Metoclopramide Baclofen Dependence Following High-Dose Therapy Fatal Cardiotoxicity Following High-Dose Cyclophosphamide Acute Anterograde Amnestic Syndrome Induced by Fentanyl Ivermectin-Induced Toxic Epidermal Necrolysis Pembrolizumab-Induced Type 1 Diabetes

2019 ◽  
Vol 54 (4) ◽  
pp. 241-245
Author(s):  
Michael A. Mancano ◽  
Jonathan Lapin ◽  
Andrew Paik
Keyword(s):  
Adverse Drug Reactions ◽  
High Dose ◽  
Drug Reactions ◽  
High Dose Therapy ◽  
Safe Medication ◽  
Temple University ◽  
The Us ◽  
Amnestic Syndrome ◽  
E Mail

The purpose of this feature is to heighten awareness of specific adverse drug reactions (ADRs), discuss methods of prevention, and promote reporting of ADRs to the US Food and Drug Administration’s (FDA) MedWatch program (800-FDA-1088). If you have reported an interesting, preventable ADR to MedWatch, please consider sharing the account with our readers. E-mail Dr. Mancano at [email protected] . Your report will be published anonymously unless otherwise requested. This feature is provided by the Institute for Safe Medication Practices (ISMP) in cooperation with the FDA’s MedWatch program and Temple University School of Pharmacy. ISMP is an FDA MedWatch partner.

Undesirable effects of polypharmacotherapy in patients with cancer-associated pain treated under palliative care

Ból ◽  
2017 ◽  
Vol 18 (4) ◽  
pp. 11-19
Author(s):  
Jarosław Woroń ◽  
Wojciech Leppert ◽  
Radosław Tymiński ◽  
Michał Graczyk ◽  
Halina Kutaj–Wąsikowska ◽  
...  
Keyword(s):  
Palliative Care ◽  
Drug Interactions ◽  
Adverse Drug Reactions ◽  
Adverse Reactions ◽  
Legal Aspects ◽  
Drug Reactions ◽  
Patients With Cancer ◽  
High Incidence

In patients with pain associated with cancer that is treated as part of palliative care, the most commonly used method is polypharmacotherapy. From the analysis of adverse reactions in this group of patients, it appears that the high incidence of adverse drug reactions occurring in this group of patients is due to the undesired drug interactions. Based on pharmacoepidemiological analysis of pharmacotherapy of 600 patients, 373 cases of adverse drug reactions were identified, with the consequence of adverse drug reactions. The paper presents an analysis of these interactions, identifying their sources and methods of prevention, and discussing their legal aspects.

Adverse drug reactions in neonates: a prospective study

2016 ◽  
Vol 101 (4) ◽  
pp. 371-376 ◽  
Author(s):  
Ana Belén Rivas ◽  
Luis Arruza ◽  
Enrique Pacheco ◽  
Antonio Portoles ◽  
Jorge Diz ◽  
...  
Keyword(s):  
Adverse Drug Reactions ◽  
Clinical Characteristics ◽  
Specific Treatment ◽  
Drug Dose ◽  
Study Data ◽  
Drug Reactions ◽  
High Incidence ◽  
Caffeine Citrate ◽  
Feed Intolerance ◽  
A Prospective Study

AimTo investigate the frequency and characteristics of adverse drug reactions (ADRs) in hospitalised neonates to obtain a better understanding of and improvement in neonatal healthcare.MethodologyA prospective cohort study. Data were collected on 313 neonates and 2166 drug prescriptions. Clinical characteristics of patients, drugs administered and ADRs were prospectively recorded and analysed. Informed consent was obtained in all cases.Results116 different ADRs were detected. 17% of the neonates experienced at least one of these ADRs. Systemic antimicrobials and caffeine citrate were the drugs that most commonly caused ADRs. According to the ADR Severity Assessment Scale, 41% were mild, 42% were moderate and 17% were severe. Of the ADRs identified, 11% were classified as ‘certain’ by the Naranjo method and 20% were classified as ‘defined’ by the Karch and Lasagna modified algorithm. Most of the ADRs detected were related to feed intolerance, phlebitis and tachycardia. Most were acute (73%) and lasted between 1 and 7 days (39%). After the occurrence of an ADR, it was necessary to initiate specific treatment in 44 cases, discontinue the drugs involved in 30 cases, and reduce the drug dose in another 30 cases. An association was shown between the number of drugs prescribed and ADR onset.ConclusionsThere is a high incidence of ADRs in hospitalised newborns, which increases with the number of prescriptions.

Panhypogammaglobulinemia Associated with Phenytoin Therapy;Status Epilepticus after Abrupt Withdrawal of High-Dose Gabapentin Therapy;Thalidomide-Induced Neuropathy;Ergot Toxicity as a Result of Over-the-Counter Drug Use;Systemic Absorption of Ophthalmic Medication Leads to Child's Overdose;Risperidone-Induced Hyperprolactinemia

2003 ◽  
Vol 38 (3) ◽  
pp. 199-270 ◽  
Author(s):  
Joel Shuster
Keyword(s):  
Status Epilepticus ◽  
Drug Use ◽  
Adverse Drug Reactions ◽  
Systemic Absorption ◽  
High Dose ◽  
Drug Reactions ◽  
Abrupt Withdrawal ◽  
Over The Counter

The purpose of this feature is to heighten awareness of specific adverse drug reactions (ADRs), to discuss methods of prevention, and to promote reporting of ADRs to the FDA's medWatch program (800-FDA-1088). If you have reported an interesting preventable ADR to medWatch, please consider sharing the account with our readers.

Sign in / Sign up

Export Citation Format

Share Document